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Introduction 
Effective management of dystocia in cattle is complicated by the limited 
availability of tocolytic drugs, which act to reduce myometrial tone and facilitate 
manipulation of the fetus and exteriorization of the uterus during cesarean section. Since 
the prohibition in 1997 in Europe and Canada of clenbuterol, another ~2 agonist used as a 
tocolytic in human medicine, terbutaline, has been employed only experimentally in 
veterinary medicine. Its utilization is problematic due to a paucity of pharmacokinetic 
information that can be used to estimate appropriate tissue residues. Such information is 
particularly relevant to terbutaline because of the history of abuse associated with its 
close relative, clenbuterol. While accurate withdrawal times can only be calculated by 
extensive sampling of a variety of relevant tissues, preliminary estimates can be obtained 
by investigating the serum pharmacokinetics after intravenous administration of a single 
dose. In addition to supporting estimation of withdrawal times, the availability of such 
pharmacokinetic data also will facilitate the design of future experiments investigating 
the distribution into milk, and the pharmacodynamic properties and safety of terbutaline. 
Therefore, the goal of the study was to determine the serum pharmacokinetics of 







Dystocia can be defined as difficult parturition due to prolonged first or second 
stage labor, impedance of the fetal passage through the birth canal, or the necessity of 
assistance for delivery.53•55•69 The first stage of parturition consists of progressive 
relaxation and dilatation of the cervix (average duration of 6 hours).69 The calf is 
delivered during the second stage of parturition after rupture of chorioallantoid and 
amnionic membranes and application of intense abdominal pressure and myometrial 
contractions by the dam (average duration of 2 to 4 hours).69 
Dystocia in cattle is considered a medical emergency and commands prompt 
resolution to afford the optimum prognosis for dam and fetus. The overall incidence of 
bovine dystocia ranges from 3-25 %, and first-calving heifers are most commonly 
affected because they have often not yet reached skeletal maturity.50 Since the most 
common cause of calf mortality during the first 96 hours of life is dystocia, or injuries 
resulting from prolonged delivery,7•68 a high incidence within a herd could have a strong 
negative economic impact. Also, cattle experiencing dystocia have been reported to have 
a subsequently reduced conception rate.69 
2 
Etiology 
The etiology of dystocia in cattle is usually multifactorial and includes maternal 
factors, fetal factors, or a combination of both. In large animals, fetal causes of dystocia 
such as malpresentation, malposition, malposture or fetopelvic disproportion occur more 
commonly than those involving the dam.55 Some examples of maternal causes include 
primary or secondary uterine inertia, abnormalities of the pelvic canal (inadequate size, 
pelvic deformities), incomplete dilatation of the cervix, stenosis of the vulva and uterine 
torsion.69 
Management 
History, length of gestation and duration of labor combined with a good physical, 
rectal and vaginal examination are necessary before attempting to manage cattle dystocia. 
Assessment of calf viability is also required prior to selection of the appropriate method 
of delivery.69 Obstetrical procedures available for management and correction of 
dystocia include manipulation (repulsion, rotation, version, rectification of postural 
defects), extraction (mechanical), fetotomy, and as a last resort, cesarean section. 
However, the use of tocolytic drugs to relax the contracting pregnant uterus or undilated 
cervix could potentially represent another alternative for the management of bovine 
dystocia. Indeed, in cases of high uterine tone or intense myometrial activity, obstetrical 
manipulations can be very difficult to accomplish and, in these circumstances, the use of 
a myometrial relaxant could allow better access and easier manipulation of the fetus, or 
facilitate exteriorization or detorsion of the uterus during cesarean section. 
3 
History & Status of Clenbuterol 
Clenbuterol is a J32 adrenergic agonist that was used in Europe and Canada as a 
bronchodilator in horses or as a myometrial relaxant in cattle and sheep.29•43 In a study 
conducted by Jonker, it was administered intravenously in 219 cows affected with fetal 
malpresentations (n=37), malposture (n=l 12), or uterine torsion (n=70).29 The successful 
rate of vaginal delivery was 84 % (76/91) for malpresentations and malpostures and 77 % 
(70/91) for uterine torsion.29 Good myometrial relaxation was obtained which made 
obstetrical manipulations easier and shorter for the veterinarian, and less traumatic for the 
dam.29 Other recorded benefits included a lower need for epidural anesthesia and 
significantly lower incidence of retained fetal membranes.29 A significant decrease of 
bovine myometrial activity was observed for at least 30 minutes after administration of 
clenbuterol in another study.43 
Despite its aid for manual correction of bovine dystocia, clenbuterol has also been 
used illegally in food animals as a growth promoter (repartitioning agent) to reduce fat 
deposition, increase lean meat, and improve feed conversion efficiency.33'
44 
To avoid the 
potential for human intoxication after consumption of liver or skeletal muscles of cattle 
treated with clenbuterol, its use was prohibited in 1997 in Europe and Canada. Common 
clinical signs associated with clenbuterol intoxication in humans include muscle tremors, 
tachycardia, and heart palpitations. 11 •62 In the United States, this uterine relax.ant has 





In human medicine, many drugs have been employed to treat premature labor and 
reduce perinatal morbidity and mortality.42 In an attempt to prevent the after-effects of 
premature delivery, attention logically has centered on efforts to find safe and effective 
tocolytic drugs. Beta 2 adrenergic agonists (ritodrine, terbutaline, isoxsuprine, 
epinephrine), calcium antagonists (magnesium sulfate), calcium-channel blockers 
(nifedipine), prostaglandin synthetase inhibitors (indomethacin), and oxytocin antagonists 
(atosiban) represent the classes of myometrial relaxants investigated. These studies 
involve the administration of different drugs at variable dosages, routes of administration, 
and variable efficacies while noting adverse effects associated with their use. The 
majority of clinical trials performed in the United States involve the utilization of '32 
adrenergic agonists such as terbutaline or ritodrine, 10•15.54 the latter being the only drug 





The effects of different tocolytic drugs has been investigated only experimentally 
in domestic animals. A significant proportion of published studies used a sheep 
d I 1,3.4,46.48,56 "bl d h . l . . h rt t t· (5 th mo e , poss1 y ue to t etr smal size, docile nature, s o ges a 10n mon s 
compared to 9 months in the bovine) and low cost. 
Based on the literature, many tocolytic drugs have been used in domestic animals. 
Ritodrine, terbutaline, magnesium sulfate, and nifedipine are reported most 
commonly.1.4'19'60 Experimental trials using isoxsuprine, epinephrine, indomethacin and 
atosiban have been reported less frequently. 20•46.48•56 Each drug has advantages and 
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disadvantages of various degrees, hence there is no ideal tocolytic drug. However, 
choosing the best myorelaxant for management of dystocia in large animals should be 
based on defined criteria such as efficacy, safety, availability, existing parenteral 
formulation, and cost (Table 1). 
Calcium-channel blockers appear to be effective as myometrial relaxants in the 
ewe. 19 However, the product is only approved for humans and does not come in an 
injectable formulation. Oral administration in ruminants is undesirable due to the effects 
the ruminal flora may have of the drug metabolism. Magnesium sulfate has been used in 
domestic animals, however it appears to be less efficacious than (32 agonists.
1 
Commercially available sources of magnesium in veterinary medicine include an oral 
paste (Magnagel)/ a powder (Carmilax),b or a salt (Epsom® salts).c Intravenous 
preparation of magnesiumd approved in veterinary medicine are combined with calcium 
because hypomagnesemia is frequently accompanied by hypocalcemia in large animal 
species. Magnesium sulfate has been administrated IV in 15 ewes, however, no 
information or reference concerning the drug used in the study was provided.1 To the 
author's knowledge, Epsom® salts has not been reported to be administered parenterally 
in domestic animals and needs further investigation. The efficacies of isoxsuprine and 
epinephrine to relax the myometrium have not been well demonstrated in domestic 
animals. Due to their non-specific action on f3 agonist receptors (f31 and f32), they also 
induce significant adverse effects.5•48•56 Indomethacin and atosiban are approved only for 
humans and may be difficult to administer intravenously because of drug formulation and 
dosage requirements.37 However, both induce myometrial relaxation with fewer side 
effects than f32 agonists, and may represent potential tocolytic drugs to investigate further 
6 
in domestic animals.20•37•46 Beta 2 agonists (ritodrine, terbutaline) are reported to be very 
efficacious for uterine relaxation in domestic animals. 12•52•60 Ritodrine is expensive, not 
available in the United States, and causes significant maternal and fetal side effects.17•60 
Terbutaline is available in the United States and is formulated for parenteral 
administration. Variable but overall moderate adverse effects have been associated with 
its administration in veterinary medicine.4•14 Despite the higher expense, terbutaline was 
selected among the other tocolytic drugs and investigated for tocolytic use in bovine 
obstetrics based on its efficacy to relax the myometrium in domestic animals, moderate 
adverse effects associated with its administration, and the availability of a parenteral 
formulation of this drug (Table 1). 
Table 1. Characteristics of tocolytic drugs 
Tocolytic Efficacy Adverse Drug Parenteral Cost 
effects availability formulation (adult cow) 
Nifedipine +++ ++ + No $2.00 
Mg Sulfate ++ ++ + Yes < $ 3.00 
(Epsom salt) 
Isoxsuprine + +++ + No <$ 1.00 
Epinephrine + +++ +++ Yes $5.00 
Indomethacin ++ + + No $40.00 
Atosiban ++ + + Yes $ 8.00 
Ritodrine +++ +++ Yes $ 32.00 
Terbutaline +++ ++ +++ Yes $ 50.00* 




*: Terbutaline sulfate, Brethine ® 
Considerations: 
The ability of a drug to relax the myometrium was based on the quality and duration of relaxation, and the 
number of studies reporting significant myometrial relaxation in domestic animals. Adverse effects were 
evaluated by total number and severity. Drug availability was based on whether the product was available 
in the United States. The cost of a particular drug was determined for an adult bovine with an average body 




Terbutaline [1-(3,5-clihydroxyphenyl)-2-t-butylamino ethanol] is a synthetic 
sympathomimetic amine that selectively stimulates~ adrenergic receptors, particularly ~2 
receptors located in bronchial, vascular and uterine smooth muscles, rather than (3 1 
receptors located in cardiac muscle. 16•51 Stimulation of ~2 receptors results in relaxation 
of smooth muscle. When administered either orally or intravenously, the molecule exists 
as a mixture of 2 stereoisomers (enantiomers), however only the (-)enantiomer exerts the 
desired pharmacological effects, while the ( + )enantiomer is devoid of effects in the 
pharrnacodynamic test models used.9 Beta 2 receptors can bind ~ agonist drugs at 3 
points on the molecule: the ~ hydroxyl group, aliphatic nitrogen, or the aromatic ring 
(Figure 1).61 







The biological activity of terbutaline is due to the aromatic ring that is substituted 
with a hydroxyl group which binds the J3 adrenergic agonist to its receptor.61 The 
biological activity is also dependent on the ionization status of the molecule. The 2 
phenolic groups of the molecule have a pKa value of 8.8 and 11.2, and the aliphatic 
amine pKa is also alkaline at 10.1.61 Thus, the drug is in an ionized form in blood 
(pH=7.4) after intravenous administration, according to the Henderson-Hasselbalch 
8 
equation. 16·54•61 Plasma or serum protein binding for terbutaline is reported to be low at 
14 to 25%.51 
The tocolytic effect of ~2 agonists is mediated by activation of adenyl cyclase that 
converts adenosine triphosphate (ATP) to intracellular cyclic adenosine monophosphate 
(cAMP).63 The rise in cAMP activates the enzyme cAMP dependant protein kinase and 
stimulates the removal of myometrial intracellular calcium. Activity of myosin light-
chain kinase (MLCK) is also reduced and myometrial relaxation occurs.
63 
Terbutaline undergoes hepatic metabolism. In humans and dogs, it is conjugated 
to sulfate and in rats, primarily to glucuronic acid.47•64 Terbutaline is excreted 
predominately by the kidneys. The drug can cross the placental barrier in women. Fetal 
plasma levels up to 55 % of the maternal plasma level were reported in one study 
involving 10 women following the administration of the ~2 agonist.
28 To the author's 
knowledge, there is no study published on fetal plasma concentration of terbutaline in 
domestic animals. Therefore, the transfer of terbutaline across the placenta in domestic 
animals is unknown. Approximately 1 % of the dose administered to pregnant women is 
excreted in breast milk.45 Excretion of terbutaline in the mammary gland of domestic 
animals has not been reported and needs further investigation. 
Indications in human & veterinary medicine 
Terbutaline is widely used in human medicine for treatment of bronchopulmonary 
disorders involving bronchospasms such as asthma, chronic bronchitis or emphysema. 
Many studies involving women in preterm and term labor investigated terbutaline as a 
t Olyt. agent 6•15•26•57 I b 1· d · · d · 1 · oc 1c . n women, ter uta me a m1mstere mtravenous y m emergency 
situations, rapidly stopped uterine contractions. 26•36 
9 
In veterinary medicine, terbutaline is used as a bronchodilating agent in the 
treatment of cardiopulmonary diseases such as tracheobronchitis, allergic bronchitis, 
pulmonary edema, and collapsing trachea in small animals.51 This drug is also used for 
treatment of bronchoconstriction in horses suffering from chronic obstructive pulmonary 
disease (COPD) also named recurrent airway obstruction (RA0).51 The use of 
terbutaline in domestic animals as a tocolytic agent is limited and only experimental. 
Very few studies describe its effect on uterine blood flow and myometrial activity in rats 
and ewes. 12•14 
Adverse effects in human & domestic animals 
Adverse effects (primarily cardiovascular and respiratory) remain a major 
consideration in the use of 132 agonists to arrest premature labor in human patients.
42 
Adverse effects reported in women following the administration of terbutaline include 
tremors, vomiting, tachycardia, premature ventricular contractions, hypotension, 
hyperglycemia, hyperinsulinemia, metabolic acidosis, hypokalemia, hypocalcemia, 
decreased glomerular filtration rate and pulmonary edema. 10•30•42 The mechanism by 
which pulmonary edema develops is still unknown but is most likely multifactorial. The 
main contributing factors include an increased blood volume (35-40 % ) in pregnancy, the 
stimulation of the renin-angiotensin-aldosterone system and antidiuretic hormone 
production by ~ agonists (terbutaline), increasing fluid retention.42 Other factors have 
also been suggested.34 Fetal tachycardia and hyperglycemia have also been reported 
following maternal administration of terbutaline.25•28 However, this ~2 agonist was found 
to be beneficial in a fetus with prolonged bradycardia. 27 
10 
In veterinary medicine, maternal and fetal side effects appear to be similar but 
overall lower in severity compared to those reported in human medicine. Continuous 
infusion of 1500 micrograms (- 2 µg/kg) of terbutaline over 30 minutes in pregnant ewes 
caused a transient maternal tachycardia and hypotension in 2 studies. 3.4 Other maternal 
and fetal adverse effects included metabolic acidosis, hyperglycemia, and lactic 
acidemia. 3 Administration of a bolus of 250 ug of terbutaline intravenously in 5 near-
term pregnant ewes induced significant but transient maternal tachycardia and systemic 
hypotension, and decreased pulse pressure and blood flow in the main uterine artery.14 
Phannacokinetic disposition in humans & domestic animals 
Many studies have investigated the pharmacokinetics of terbutaline in 
humans.9'36.49 Different patients (pregnant women in premature labor, healthy men, 
asthmatic children), dosages, routes of administration (oral, IV, subcutaneous (SC), 
bl. 1· ) db d fl 'd ( l . . · t d2.9,24364s49 ne u 1za 10n , an o y m s p asma, serum, unne) have been mvest1ga e . · · · 
Relatively few trials have been conducted in domestic animals and these have been 
restricted to the investigation of intravenous pharmacokinetics in dogs, rats
47 
and horses66 
and oral pharmacokinetics in broiler chickens39 and dairy cattle. 67 The latter study was 
very limited in scope, published only as a doctoral thesis, and failed to provide sufficient 
data to allow estimation of withdrawal times in either meat or milk. The pharmacokinetic 
determinants described in these studies included therapeutic plasma concentration, 
bioavailability, volume of distribution, clearance (renal, total), mean residence time, and 
terminal half-life of terbutaline. 
Therapeutic plasma concentration is based on the observed relationship between 
the measured plasma concentration of the drug, its pharmacologic and toxic effects.54 A 
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common tocolytic dose for terbutaline in women is reported to be ranging between 200 
and 250 micrograms. 9•26•35•36•42.49.57 Cessation of uterine contractions in women in 
preterm labor occurred when the plasma concentration of terbutaline ranged between 5-
15 ng/ml in one study8 and between 12.8 and 31.5 ng/ml in another study.36 After 
administration of oral terbutaline once a day for 6 days to dairy cows at 50 µg/kg and for 
14 days to broiler chicken at 10 µg/kg, plasma concentrations of terbutaline were 4 ng/ml 
and 42.8 ng/ml, respectively.38•67 In a study involving 6 horses, median maximal serum 
terbutaline concentration was 9.3 ng/ml after administration of 10 µg/kg intravenously.66 
Bioavailability can be defined by the degree to which a drug becomes available to 
the target tissue and is dependent on the route of administration.54 In men, most oral 13 
agonists are well absorbed (up to 75 %), except for terbutaline (14.8 %).9 Peal< plasma 
concentration is generally reached within 1 to 4 hours.45 Due to extensive first-pass 
sulphation occurring in the liver, the bioavailability is low (8-15%).2•45.49 The intestinal 
wall (mucosa} epithelium) metabolism and the presence of food may affect the absorption 
of terbutaline after oral administration, contributing to a low bioavailability.2'48 In the 
equine species, bioavailability of oral terbutaline was close to zero in one study.65 To 
avoid the first-pass sulfation, tocolytic drugs have to be administered parenterally (IV, 
SC), thereby increasing their bioavailability to approximately 100 %.35•45 In general, 
pulmonary administration of ~2 agonists with aerosol or nebulization shows 10 to 20 % 
absorption, and a maximum plasma peak concentration at 2 to 4 hours following 
admi ni strati on. 45 
Mean residence time (MRT) can be defined as the mean time required for an 
intact drug molecule to transit through the body.36 A MRT value of 9 hours was found in 
12 
healthy men,49 and a value of 3.4 hours was reported in pregnant women.36 In horses, the 
MRT was 30 minutes on average in one study.66 
The volume of distribution represents the calculated body space available for 
distribution of a drug and varies from 0.8 to 1.9 Ukg in human and domestic 
animals9·24·36·49·66 Because of the drug's low protein-binding property, the volume of 
distribution is not likely to be changed, even in the presence of a low serum albumin 
concentration. 51 •58 
Total body clearance corresponds to the volume of distribution of a drug in the 
body cleared of a substance per unit of time and includes mainly renal and hepatic 
clearances (and others). Total body clearance has been reported to be 0.16 to 0.19 
Uh/kg9'24 in humans and approximately 1.9 Uh/kg in horses.66 Renal clearance 
h 1 · f · 53 represents t e vo ume of blood cleared of a substance by the kidney per umt o time. 
Terbutaline is filtered and actively secreted by the kidney.8 The renal clearance of the 
( + )enantiomer of terbutaline is greater than the (-)enantiomer, showing the 
stereoselecti vity of its excretion. 9 In men and dogs, more than 90 % of a parenteral dose 
of terbutaline is excreted in the urine, 66 % of which is unchanged drug. Only 1 % is 
excreted via bile. 64 
Terminal half-life can be defined as the time required for a given plasma 
concentration of a drug to decline by 50 %. Terminal half-life for terbutaline reported in 
the literature in horses was 1.2 hour66 and varied from 3.7, to 12.1, 14 or 17 hours in 
humans.9,24,36.49 
13 
M etlzods for assessment of phannacokineti.cs of terbutaline 
In the majority of the pharmacokinetic studies conducted on terbutaline, serum or 
plasma was obtained after centrifugation of whole blood collected via an intravenous 
catheter placed in a peripheral vein (jugular, femoral). The concentration of terbutaline 
present was measured mainly via 2 different techniques: gas chromatography with mass 
spectrometry (GC-MS)8•9•24•66 or high pressure liquid chromatography (HPLC) using 
Ultra-Violet (UV) or fluorescence detection.22•32•59 Either method appears to be adequate 
to determine the concentration of terbutaline in serum, plasma or urine, although GS-MS 
is more sensitive (0.15 ng/ml)66 than HPLC fluorescence detection (0.3 ng/ml)32 or 
HPLC-UV (0.1 µg/ml). 22 To the author's knowledge, there is no reported 
pharrnacokinetic study of terbutaline using milk either from humans or domestic animals. 
However, HPLC and ELISA were used in a study detecting the presence of J32 agonists 
(clenbuterol, salbutamol and terbutaline) in milk replacer for calves.13 
Basic pri,iciples of High Liquid Performance Chromatography (HPLC) 
Chemical separation 
Certain compounds have different migration rates that are determined by the 
choice of a particular stationary phase and mobile phase. The stationary phase in HPLC 
refers to the immobile packing material contained within the chromatographic column 
over which the mobile phase continuously flows. 31 The mobile phase in HPLC refers to 
the solvent and carrier of the compounds present in the sample solution that passes 
continuously and under high pressure through the chromatographic column. 23•31 The 
chemical interactions of the stationary phase and the sample solution contained within the 
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mobile phase will determine the degree of separation of the components present in the 
sample solution. For example, samples that have stronger interactions with the stationary 
phase than the mobile phase will elute from the column less quickly, thus their retention 
time will be longer. The inverse is also true. Various types of stationary phases are 
commercially available and include liquid-solid (adsorption), liquid-liquid, and size 
exclusion. Liquid-solid stationary phase functions on the basis of polarity. Polar 
compounds that possess functional groups capable of strong hydrogen bonding will 
adhere more tightly to the stationary phase than less polar compounds.23 Therefore, less 
polar compounds will elute from the column faster than highly polar compounds. 
However, when reverse phase HPLC is used (C18 column), less polar compounds will 
elute from the column slower than higher polar compounds. 
Identification 
Identification of a compound via HPLC involves the selection of a detector and 
the development of a separation assay. The detector is the component of an HPLC that 
emits a response to the compounds as they elute from the stationary phase and 
subsequently signals a peak on the chromatogram.23 Some examples of the more 
common detectors include Ultra-Violet, Refractive Index, and Fluorescent. 
The separation assay should be developed to obtain a clean peak of the target 
compound on the chromatogram with a reasonable retention time (usually 10 to 20 
minutes). A known compound must be utilized in order to assure identification of the 
unknown target compound. Consequently, the selection of the parameters for the 
separation assay is accomplished by researching the literature for previously published 
methods and trial and error. 
15 
Qlla,itification 
Quantification is the process of determining the unknown concentration of a 
compound using a known solution of pre-determined concentration.23 A series of known 
concentrations of the target compound is injected onto the HPLC for detection in order to 
obtain a standard curve. The chromatograph of these known concentrations will give a 
series of peaks that correlate to the concentration of the compound injected. The area 
under each peak (AUC) is then calculated, using the trapezoidal method [0.5·(ti+t - ti) · 
(Ci+t - Ci)] where ti+t and ti are times associated with sequential blood samples and Ci+t 
and Ci are the corresponding sample concentration.39 The AUC (or the ratio of the AUC 
of the target compound and an internal standard) can be plotted with the known 
concentrations (target compound) on a graph. A best-fit line can be derived and the 
equation generated, also called polynomial response function (format: y=mx + b ), will 
represent the calibration curve equation.23 When a sample of unknown concentration "y" 
of the target sample is injected onto the HPLC, the chromatograph gives a peak output of 
area "x". The area under the curve "x" is then placed in the calibration curve equation, 





Materials and Methods 
Six near-term pregnant beef cows purchased from a local livestock market were 
used in the study. Prior to parturition, animals were housed together in an outdoor large 
animal resource facility for 3 days. Nonnal health and pregnancy status were determined 
by physical examination and rectal palpation. Accurate weights were obtained and 
ranged from 437 to 664 kg. Parturition was induced on day 2 in order to synchronize 
delivery time. Induction of parturition was performed by administration of 
dexamethasone sodium phosphate at 20 mg/cow intramuscularly (IM), and dinoprost 
tromethamine (PGF2a) at 25 mg/cow ™· On day 3, the cows were transported to the 
Oklahoma State University (OSU) Boren Veterinary medical teaching hospital food 
animal barn where they were maintained in individual stalls (under the supervision of the 
principal investigator) until parturition. Each cow involved in the present experiment 
was cared for according to the guidelines of the Institutional Animal Care and Use 
Committee of Oklahoma State University. They were fed ad libitum grass hay and a 





Pharmacokinetic experiments were initiated within 24 hours post-partum. A 16 
ga, 3 inch and a 12 ga, 5 inch intravenous catheter were placed in the right caudal 
auricular (ear) and jugular veins of each animal, respectively. Terbutaline sulfate 
(Brethine®t was then administered as an IV bolus via the ear vein catheter at a dose of 5 
µg/kg of body weight over a 30 second time period. 
Blood samples were collected from the jugular catheter before drug 
administration and 5, 10, 20, 30, 45 minutes, and 1, 2, 3, 4, 6, 8, 12, 16, 18, 24, 48, 72 
hours thereafter. After collection of each blood sample, the catheter was flushed with 5 
ml of heparinized saline solution (10 U heparin/ ml of saline 0.9 % ). All samples were 
collected into evacuated glass tubes without additive. Clotted blood samples were 
centrifuged (600 g for 15 minutes) and serum was harvested in plastic tubes and stored at 
-70°C until analysis. 
Experiment II 
A second experiment was performed using the same 6 cows, approximately 8 
months after the initial experiment, using a higher dosage of 0.5 mg/kg of terbutaline 
sulfate (Sigma)r administered IV once. Prior to beginning the experiment II, this dosage 
was administered to a 2-year-old intact male alpine goat to screen for potential adverse 
effects. The goat's heart rate, respiratory rate and general health were monitored closely 
for 4 hours after the administration of the ~2 agonist (Figure 2-3). 
For the second experiment, the cows were neither pregnant nor lactating. Each 
dose of terbutaline sulfate crystalline powder was measured with precision by using an 
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electronic scale. r The powder was then reconstituted using sterile water to obtain a final 
concentration of 12.5 mg/ml of terbutaline. The solution was passed through a 0.2 µm 
filter during the intravenous administration via the ear vein catheter. Blood collection 
timing was the same as in experiment I, except that the 72 hours blood sample was not 
collected. Heart rate and general health of each cow were monitored closely in the hour 
following the administration of terbutaline. 
Terbutaline assay 
The concentration of terbutaline in serum and milk samples was measured by high 
performance liquid chromatography (HPLC) with fluorescence detection, using a 
combination of 2 previously published methods with slight modifications in order to 
optimize the assay.22•32 
Materials 
Terbutaline sulfate, betaxolol, acetonitrile, and methanol were obtained from 
Sigma. g Terbutaline sulfate for injection (Brethine®) was manufactured by Novartis 
Pharmaceuticals (Summit, NJ, USA). Solid-phase extraction columns were 6 ml 
polypropylene columns packed with 1 g of C18 bonded phase manufactured by Varian 




One hundred microliters of an internal standard solution (betaxolol, 1 µg/ml) and 
1 ml of acetonitrile were added to 1 ml of each serum sample and vortexed for 30 
seconds. Each sample was centrifuged at 3000g for 15 minutes at 4 degree C0 • The 
serum samples were injected into C18 solid-phase extraction columns that had been 
preconditioned twice with 3 ml of ethanol and 3 ml of distilled water. After loading of 
each sample, the columns were rinsed twice with 3 ml of distilled water. The serum 
samples were eluted with 1 ml of ethanol containing 50 mM of ammonium chloride 
buffer (pH 8.5, 95:5 vol/vol) and placed in receiver tubes in a vaccum manifold. The 
solvent was removed by drying the samples by speed-vac at 45 degrees C0 • The dried 
residue was reconstituted with 100 µ.l of mobile phase [25 mM sodium phosphate buffer 
(pH 7.4): methanol (77:23 vol/vol)], vortexed, and centrifuged at 13,400 g for 2 minutes. 
The supernatant was transferred into new tubes and stored at -20 degrees C. The samples 
were passed through the C18 solid-phase extraction columns within the mobile phase and 
terbutaline was detected via fluorescence at excitation and emission wavelengths of 224 
and 310 nm, respectively (Appendix A). 
Standard curve 
Standard curves (0, 25, 50, 100, 250, 500, 1000, 2000 ng of terbutaline/ml) were 
prepared by adding known amounts of terbutaline sulfate to drug-free bovine serum and 
measuring terbutaline concentration as described in the extraction protocol. The 
detection limit was 25 ng/ml. 
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Pliannacokineti.c analysis 
Concentration-time data were subjected to pharmacokinetic analysis by use of 
noncompartmental methods, based on statistical moment theory. Terbutaline 
phannacokinetic parameters in the bovine were calculated with standard formulae. The 
area under the curve (A UC) was measured by trapezoidal method described 
elsewhere.39'54 The volume of distribution at steady state (Vdss) was calculated via the 
formula V dss = Cl8 • MRT.54 The fonnula C18 =Dose/ AUC was used to calulate total 
body clearance (C18 ).
54 The mean residence time (MRT) was calculated via the formula 
MRT = AUMC / AUC where AUMC represent the area under the moment curve.54 The 





The concentration of terbutaline in the serum samples of experiment I was too 
low to be determined, despite a sensitive assay (detection limit: 25 ng/ml). Therefore, no 
pharmacokinetic data could be calculated. 
The results of the trial administration of terbutaline to a healthy goat, prior to 
experiment II are depicted in Figures 2-3. 
In experiment II (bovine species), the serum concentration-time curves 
(individual, mean) obtained for all 6 cows after IV bolus administration of 0.5 mg/kg of 
terbutaline are shown in Figures 5-6. After preliminary analysis, the concentration of 
terbutaline in the first 2 cows was below the detection limit of the assay after 
approximately 30 minutes following administration of the ~2 agonist. Therefore, the 
assay was performed only on the serum samples collected up to 4 hours (240 minutes) in 
the 4 remaining cows. 
Significant tachycardia (mean heart rate: 174 +/- 10.4 beats/min) was found at 
approximately 2 minutes following the administration of terbutaline (Figure 4), 
compared to baseline (58 +/- 7 .5 beats/min). Cardiac arrhythmias and muscle 
fasciculations were also noted in cows 1 and 5 respectively, and lasted approximately 45 
minutes. Their recovery was uneventful and did not necessitate therapy. 
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In all 6 cows, the mean serum concentration of terbutaline detected approximately 
5 minutes after the IV bolus of terbutaline was 708.22 +/- 509.6 ng/m.L (Table 2). The 
mean area under the curve to infinity (AUCinf) was 13692.8 +/- 6869 min·ng/mL 
(Table 2). The mean half-life for terbutaline was found to be 6.93 +/- 2.4 minutes. The 
MRT was calculated to be 6.75 +/- 3.6 minutes. The total body clearance was 43.29 +/-
17 .2 mLJmin/kg. The volume of distribution at steady state ranged from 0.080 to 0.805 
Ukg with a mean of 0.34 +/- 0.28 Ukg. 
Results of noncompartmental analysis of the distribution and elimination of 
terbutaline following IV administration to 6 healthy cows are depicted graphically in 
Figure 7. 
Table 2-Pharmacokinetic analysis of Terbutaline following IV administration (O.S 





























































*Values are expressed as mean+/- s.d. C,=s= serum concentration detected 5 min after the administration of 
terbutaline. AUC inf= Area under the concentration-versus-time curve to infinity. t ½=half-life. MRT = Mean 
residence time. Cl= Clearance. Vdss = Volume of distribution at steady state. 
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Figure 2-Heart rate in one healthy goat foil owing the administration of Terbutaline 
(0.5 mg/kg IV) 
250 
230 - 210 C: ·e 190 
) 170 --
~ 150 




0 1 2 3 4 5 10 15 120 240 
Time (min) 
Figure 3. Respiratory rate in one healthy goat following the administration of 
Terbutaline (0.5 mg/kg) 
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Figure 5. Terbutaline serum concentration after administration of O.Smg/kg IV in 
six cows 
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Chapter IV 
Discussion 
The dosage of terbutaline selected for the first experiment was extrapolated from 
the most commonly reported dose used in women for tocolysis; 250-300 µg/min for an 
average 60 kg woman (0.5 µg/kg). 26•36•57 Comparisons between the pharmacokinetics of 
terbutaline in humans and domestic animals cannot be made. In a pilot study (non-
published) using 4 late pregnant cows in which a cesarean was performed, a clinically 
detectable relaxation of the uterus was subjectively appreciated via sight and palpation, 
following a single administration of 5 µg/kg of terbutaline. 
The assay used in the first experiment (HPLC with fluorescent detection) was 
developed based on Kim32 and Herring22 and the detection limit was 25 ng/ml. Despite 
this high sensitivity, the concentration of terbutaline in the initial experimental samples 
was too low to be determined, therefore, a second experiment using an increased dosage 
was performed. 
To calculate a dosage of a drug, one required factor is volume of distribution. To 
the author's knowledge, a volume of distribution for terbutaline in the bovine has not 
been reported previously. However, it was found to be 0.9 Ukg in horses66 and from 0.8 
to 1.9 Ukg in humans.9•24•36•49 Therefore, the volume of distribution was empirically 
selected at 0.5 Ukg (500 ml/kg) for cattle. Using a target maximal serum peak 
concentration of 1 µg/ml (empirical), and given that dosage of a drug equals its serum 
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concentration multiplied by its volume of distribution (Dose= Cone. x V d), the new 
dosage of 500 µg/kg of terbutaline was calculated for the second experiment. This 
dosage was much higher than previously reported in humans and domestic animals for 
terbutaline. 3·26.49•57 •66 
According to AMDUCA,h extralabel drug use (ELDU) in veterinary medicine is 
permitted only by or under the supervision of a veterinarian, allowed only for FDA 
approved animal drugs, and can only be used for therapeutic purposes (animal is 
suffering or its life is threatened), rather than production. The extralabel drug use should 
also meet the "label requirements" of AMDUCA: name and address of the prescribing 
veterinarian, established name of the drug, specified directions for use, identification of 
the animal, the dosage frequency, route of administration, duration of therapy, cautionary 
statements, and specified withdrawal time. However, in a research setting, a non-
approved experimental drug such as terbutaline can be administered to food animals 
(bovine) as long as they do not enter the human food chain. 
Induction of severe adverse effects (especially cardiovascular) using 100 times the 
initial dose of terbutaline was considered. However, the dose at which 50 % of animals 
die (LDso) in rats for this ~2 agonist has been reported to be much higher (165 mg/kg).i 
To screen for possible adverse or fatal effects in a ruminant species, a pilot study using 
one 2-year-old healthy intact male alpine goat was conducted using 0.5 mg/kg 
administered via a jugular catheter over a 30 second time period. The goat showed 
significant tachycardia and tachypnea associated with terbutaline administration (Figures 
2-3) but recovered uneventfully within 4 hours. Tachycardia associated with terbutaline 
administration in the goat and all 6 cows involved in the seconq experiment could be a 
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direct effect of terbutaline on the cardiac muscle via the stimulation of 131 receptors, or 
secondary to systemic vasodilation (leading to hypotension) in response to 132 
adrenoreceptor stimulation of smooth muscle tissue in blood vessels. Cardiac 
arrhythmias found in cow 1 were most likely due to the stimulation of 131 receptors 
located in cardiac muscle. The cause of muscle fasciculations exhibited by cow 5 after 
terbutaline administration may be due to hypokalemia, as reported in humans by Katz.
30 
Suspected mechanisms leading to hypokalemia include a direct effect of the drug on the 
pancreatic islet cells inducing insulin release, stimulating cellular potassium uptake.
10 
Other reported hypothesis include a direct stimulation of (32 receptors in skeletal muscle, 
leading to direct cellular potassium uptake10•66 
High pressure liquid chromatography data obtained in experiment II showed a 
variable serum concentration peak of terbutaline averaging 708.22 +/- 509.6 ng/mL, 5 
minutes following its administration (Figure 6, Table 2). The exponentially decreasing 
curve following the peak was unexpectedly steep. Serum terbutaline concentrations were 
below the detection limit of our assay after 30 minutes ( on average) following its 
administration (Figures 5-6). A similar decline in serum drug concentration was 
reported in equine species, although the drug was administered as a continuous infusion 
for an average of 33 minutes (10 µg/kg total) 66 instead of an IV bolus. 
The pharmacokinetic (PK) analysis of concentration-time data was performed by 
use of a noncompartmental model. This particular model was selected based on the 
limited number of concentration-time data points obtained per cow. This model analyses 
using statistical moment theory.54•58 Furthermore, the phannacokinetic data do not need 
to be adjusted for the higher dosage (0.5 mg/kg) due to the fact that linear or first-order 
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kinetics is assumed with a noncompartmental model.58 However, evidence of two 
different phases (distribution and elimination) was found when concentration-time data 
were plotted in a graph using a logarithmic scale (Figure 7). The two different phases 
suggested that a multicompartment pharmacokinetic model might be more appropriate for 
the PK analysis of terbutaline in bovine species than a noncompartmental model. 
Noncompartmental and one, two and three compartmental models have all been used for 
the pharmacokinetic analysis of terbutaline in other reports. 18•35•66 
In experiment II, the mean area under the curve (AUC) was 13692 ng·min/ml 
which corresponds to 228.2 µg·h/L. In order to make comparisons with the reported 
AUC for terbutaline in human and domestic animals,26•66 a "dose normalized AUC" was 
used by dividing the AUC by the total dose of terbutaline administered. The dose 
normalized AUC obtained in the experiment II was 0.81 x 10-3 h/L (228.2 µg·h/L / 
281000 µg), which was lower than the other AUC reported in humans, but similar to the 
one calculated in equine species. Indeed, in adult healthy men, the dose normalized AUC 
was calculated to be 69.71·10-3 h/L (14.5 µg·h/L/ 208 µg). 18 In horses, the dose 
normalized AUC was calculated at 1.18 x 10-3 h/L (5.37 µg·h/LJ 4525 µ,g).
66 
Differences 
in AUC may be due to modeling error.41 It may also be the result of failure to accurately 
define the terminal half life of a drug depending on the extent of which the blood 
concentration/time profile is described.41 
Variable terminal half-lives for terbutaline (1.2, 3.7, 12.1 and 17 hours) have been 
reported in human and veterinary medicine.24•36•49•66 A short half-life such as the one 
found in this experiment (t ½: 6.93 +/- 2.4 min) probably does not reflect the terminal 
elimination phase. 18 Based on Figure 7, it rather suggests a rapid half-life of distribution 
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throughout the body although this assumption remains uncertain. The variability in PK 
studies for this parameter appear to be due to the differences in duration of blood 
collection and serum concentration determination following the administration of the lh 
agonist.49 It may also depend on the achievement of a steady-state of the drug. 
The mean residence time calculated in this experiment was 6.75 +/- 3.6 minutes 
which was shorter than the MRT of 30 minutes reported in horses by Tomeke.
66 
Total body clearance for terbutaline in experiment was 43.29 +/- 17 .2 mUmin/kg 
(2.58 Uh/kg), which is comparable to that reported in horses (1.9 Uh/kg).
66 
The volume of distribution at steady state (Vdss) provides an estimate of drug 
distribution that is independent of the elimination process.40 It also represents the sum 
total of all compartmental volumes and it is used to estimate the extent of extra vascular 
drug distribution.40 The mean Vdss for terbutaline in experiment Il, 0.34 +/- 0.28 11kg, 
was lower than the reported value for this parameter in humans and domestic 
animals.9•24•36.49•66 This small Vdss (< 111kg) suggests that terbutaline does not have a 
good extravascular distribution: it remains in the vasculature at a greater extent than in 
the tissue. The small V d also suggests that the ~2 agonist should have an adequate 
watersolubility. Indeed, in the second experiment, terbutaline powder was diluted with 
sterile water at a concentration of 12.5 mg/rnL without evidence of precipitation. 
Compounding of drugs are prohibited for extra-label use in food-producing 
animals, because the drugs present a risk to the public health. To limit the cost of the 
drug due to the increased dosage, terbutaline powder (Sigma) was used in the second 
experiment to provide a parenteral formulation of the beta-2 agonist for administration to 
6 cows that did not enter the human food chain. 
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ChapterV 
Summary and Conclusions 
Dystocia in cattle could be managed by the utilization of a ~2 agonist such as 
terbutaline. This drug has been efficacious for prevention and treatment of pretenn labor 
in human medicine. However, it has only been used in an experimental manner in 
veterinary medicine. Since the prohibition of another ~2 agonist, clenbuterol, in Europe, 
Canada and the United States in food producing animals, the establishment of appropriate 
withdrawal times for terbutaline was indicated before pursuing its tocolytic potential in 
cattle. 
The serum pharmacokinetics after intravenous administration of a single dose was 
therefore investigated in cattle, as a reliable preliminary estimate for establishment of 
tissue residues. High pressure liquid chromatography with fluorescence detection was 
used to detect the concentration of terbutaline in serum samples. The data obtained 
showed that this f32 agonist disappeared abruptly from the serum after its administration. 
The limited number of significant concentration-time data points obtained per cow 
restricted the pharmacokinetic analysis to a noncompartmental model. All PK parameters 
were overall, dissimilar to those reported in the literature, with the exception of total 
clearance. The short half-life obtained was almost certainly not terminal, precluding the 




The pharmacokinetic data obtained in this experiment will be used as a basis for a 
future study in which a loading dose (30 µg/kg) and continuous IV infusion (258 
µg/h/kg) of terbutaline in six cows will be maintained to achieve a steady state of serum 
drug concentration. This may allow the recognition of a distribution and elimination 
phase in serum and a distribution phase in milk, the selection of a more appropriate 
pharmacokinetic model for this fh agonist, calculation of its terminal half-life of 
elimination and subsequently, extrapolation of withdrawal times in meat and milk. To 
prevent inaccurate measurement of terbutaline concentrations, the method of detection 
and extraction of the drug will be based on the most sensitive detection method: gas 
chromatography with mass-spectrophotometry. 
These phannacokinetic data for terbutaline in bovine species will then serve as a 
basis for future experiments designed to evaluate the pharmacodynamics and safety of 
terbutaline and will correlate uterine electromyographic responses with concentrations of 
the drug in the systemic, uterine, and fetal circulation. A pharmacokinetic-
pharmacodynamic (PK-PD) model will be constructed and then tested in a large 
population of bovine patients, with the ultimate goal of identifying demographic 
covariates that can be included in a population PK-PD model. The availability of such a 
model would allow estimation of dosage regimens appropriate for individual patients. 
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Footnotes 
a. Magnagel: magnesium chloride, PRN Phannacal, Pensacola 
b. Cannilax®: magnesium hydroxyde: Pfizer, NY 
c. Epsom® salt: magnesium sulfate·? H20, Cumberland Swan, TN 
d. Caldex 2: calcium-combination therapy containing calcium, phosphorus, magnesium, 
dextrose, Fort Dodge animal health, N.W., IA 
e. Brethine®: Terbutaline sulfate for injection (1 mg/ml), Novartis Pharmaceuticals, 
Summit, NJ, USA 
f. Electronic scale: Ohaus Analytical Plus, Aldinger company, model AP250D-O, 
Switzerland 
g. Sigma: pharmaceutical company, St-Louis, MO, USA 
h. AMDUCA: Animal Medicinal Drug Use Clarification Act 2003. 21 CFR parts 530 
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Terbutaline extraction protocol using HPLC with fluorescent detection 
Standard curve 
Standard curve concentrations are 2000, 1000, 500, 250, 100, 50, 25, and Ong/ml of 
terbutaline (TBL). 
Validation samples are six each of 25 and lOOOng/ml terbutaline. 
Each standard curve, validation and experimental sample will contain lOOug/ml betaxolol 
(BXL). 
All stock solutions are in methanol. 
Validation samples 
25ng/ml: 400ul of 500ng/ml TBL stock solution in 3600ul serum. 
1 OOOng/ml: 800 ul of 5ug/ml TBL stock solution in 3200ul serum. 
For each concentration pipet 7 500ul aliquots into glass screw-cap tubes and discard the 
rest. Use one aliquot of each concentration as a point in the standard curve. 
Standard curve: in a glass screw-cap tube: 
2000ng/ml: 200ul of 5ug/ml stock TBL in 300ul serum 
1 OOOng/ml: 1 OOul of 5ug/ml stock TBL in 400ul serum 
500ng/ml: 50ul of 5ug/ml TBL in 450ul serum 
250ng/ml: 25ul of 5ug/ml TBL in 475ul serum 
lOOng/ml: lOOul of 500ng/ml TBL in 400ul serum 
50ng/ml: 50ul of 500ng/ml TBL in 450ul serum 
25ng/ml: 25ul of 500ng/ml TBL in 475ul serum 
Ong/ml: 500ul serum 
Extraction 
• Add lOOul of lmg/ml BXL stock solution to each tube. (5ml tip #l) 
• Add 1 ml of acetonitrile to each tube. (25ml tip #2) 
• Vortex for 30 seconds 
• Centrifuge at 3000g for 15 minutes at 4 degrees C. 
• Precondition C1s solid-phase extraction columns with 2X3ml ethanol and 2X3 ml 
water. 
• Pass serum through columns. 
• Rinse columns with 2X3ml water. 
• Place receiver tubes in vacuum manifold. 
• Elute drugs from column with 1ml of ethanol:50mM ammonium chloride buffer, 
pH 8.5 (95:5, v/v). 
• Dry in speed-vac at 45 degrees C. 
• Reconstitute samples with lOOul mobile phase (5ml tip #1) and vortex. 
• Centrifuge at 13,400g for 2 minutes. 
• Transfer supernatant into a new tube. 
43 
• Store samples at -20 degrees C. 
• Run through C18 column with the following mobile phase: 25mM sodium 
phosphate buffer (pH 7.4): methanol (77:23, v/v). 
• Detect fluorescence at excitation and emmision wavelengths of 224 and 310run. 
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